ArticleJournal of the American Geriatrics Society2011
Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia.
Article in Journal of the American Geriatrics Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Trajectories of Medication Use Prior to Death in US Nursing Home Residents With Dementia.Journal of the American Medical Directors Association · 2026Article
- Prognostic predictors of mortality among individuals with advanced dementia residing in nursing homes: a prospective cohort study.BMC geriatrics · 2025Article
- Cholinesterase Inhibitor Initiation Does Not Increase the Risk of Fall-Related Injury in Older Adults Treated With Beta-Blockers: A Self-Controlled Case Series Design.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Geographic Variation of Antidementia and Antipsychotic Medication Use Among US Nursing Home Residents With Dementia.Medical care · 2024Article
- Antidementia Medication Use in Nursing Home Residents.Journal of geriatric psychiatry and neurology · 2024Article
- Anticholinergic co-prescribing in nursing home residents using cholinesterase inhibitors: Potential deprescribing cascade.Journal of the American Geriatrics Society · 2023Article
- Resident-Level Predictors of Dementia Pharmacotherapy at Long-Term Care Admission: The Impact of Different Drug Reimbursement Policies in Ontario and Saskatchewan: Prédicteurs de la pharmacothérapie de la démence au niveau des résidents lors de l'hospitalisation dans des soins de longue durée : l'impact de différentes politiques de remboursement des médicaments en Ontario et en Saskatchewan.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2020Article
- Risk for Health Events After Deprescribing Acetylcholinesterase Inhibitors in Nursing Home Residents With Severe Dementia.Journal of the American Geriatrics Society · 2020Article
- Impact of deprescribing AChEIs on aggressive behaviors and antipsychotic prescribing.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Article
- Factors Associated With Deprescribing Acetylcholinesterase Inhibitors in Older Nursing Home Residents With Severe Dementia.Journal of the American Geriatrics Society · 2019Article
- The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.Drugs & aging · 2015Review
- Use of medications of questionable benefit in advanced dementia.JAMA internal medicine · 2014Article
- Effect of medications on physical function and cognition in nursing home residents with dementia.Journal of the American Geriatrics Society · 2014Article
- Patterns and determinants of dementia pharmacotherapy in a population-based cohort of home care clients.Drugs & aging · 2013Article
- Pharmacotherapeutic management of dementia across settings of care.Journal of the American Geriatrics Society · 2013Article
- The impact of Medicare prescription drug coverage on the use of antidementia drugs.BMC geriatrics · 2013Article
- Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma.Drugs & aging · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
objectivesTo quantify the use of cholinesterase inhibitors (ChEIs) and memantine in nursing home (NH) residents with dementia upon NH admission and 3 months later and to examine factors associated with reduction in therapy.
designRetrospective cohort study.
settingNationwide sample of U.S. NHs.
participantsThree thousand five hundred six NH residents with dementia newly admitted in 2006. MEASUREMENTS: Data from pharmacy dispensing records were used to determine ChEI and memantine medication use upon NH admission and at 3-month follow-up. The Minimum Data Set was used to determine resident- and facility-level characteristics. Severity of dementia was defined using the Cognitive Performance Scale (CPS).
resultsOverall, 40.1% (n=1,407) of newly admitted NH residents with dementia received ChEIs and memantine on NH admission. Use of ChEIs and memantine on admission was significantly greater in residents with mild to moderately severe dementia (41.2%) than in those with advanced dementia (33.3%, P=.001). After 3 months, ChEI and memantine use decreased by about half in both groups (48.6% with mild to moderately severe dementia vs 57.0% with advanced dementia, P<.05). NH residents with advanced dementia were significantly more likely reduce their use of ChEIs and memantine than those with mild to moderately severe dementia (odds ratio=1.44, 95% confidence interval=1.03-2.01, P=.04).
conclusionMany NH residents with advanced dementia receive ChEIs and memantine upon NH admission, and approximately half of these decrease their medication use over the ensuing months. Further study is required to optimize use of ChEIs and memantine in NH populations and to determine the effects of withdrawing therapy on resident outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.